Richard Hampson is the Co-founder and CEO of Epinutra, an OTC healthcare discovery and development company whose mission is to improve upper digestive tract health with clinically effective supplements. Under his leadership, Epinutra has developed innovative, natural health solutions, including their flagship lozenge, that offers significant long term symptom relief to 80% of the target population.

Richard has a degree in Biology from the University of Wales at Bangor and a Ph.D. in Cell Biology from Cancer Research UK (London).

He has led scientific teams in biotech scale-ups and conducted Ph.D. and postdoctoral research at prestigious institutions, including the University of London, Harvard University, and King’s College London. As a co-inventor on two granted patents and several published applications, Dr. Hampson has over 10 years of experience in translational research and commercialization. He has also authored 20 peer-reviewed articles.